Human Metapneumovirus Treatment Guidelines

Introduction to HMPV Treatment

The American College of Physicians recommends supportive care only for immunocompetent adults with HMPV infection, as no antiviral agent has established efficacy for HMPV treatment 1
The Infectious Diseases Society of America suggests rest, hydration, and symptomatic management as the mainstays of therapy for otherwise healthy individuals with HMPV infection 1

The Centers for Disease Control and Prevention consider treating HMPV lower respiratory tract disease with ribavirin and/or intravenous immunoglobulin in immunocompromised patients, despite the lack of randomized controlled trial data supporting this approach 2, 3, 4, 5
The American Society of Hematology recommends this consideration specifically for hematopoietic stem cell transplant recipients and leukemia patients with pneumonia or lower respiratory tract involvement 2, 3
The Infectious Diseases Society of America notes that upper respiratory tract infection alone in immunocompromised patients does not typically warrant antiviral therapy 2
The American Thoracic Society reports that HMPV is frequently codetected with other pathogens in pneumonia cases, which obscures the true attributable morbidity and makes treatment decisions more complex 2, 3, 4
The Society for Healthcare Epidemiology of America states that single cases of severe disease and fatal outcomes have been reported even with treatment attempts 2, 4
The American College of Physicians notes that no general recommendation for treatment can currently be made based on available evidence 2, 3, 4, 5

The American Thoracic Society recommends oxygen therapy titrated to maintain adequate saturation, monitoring of vital signs, oxygen saturation, and respiratory status, fluid and electrolyte management, and treatment of bacterial superinfection if suspected or documented 6

The Centers for Disease Control and Prevention reports that HMPV demonstrates asymptomatic and prolonged shedding, particularly in hematopoietic stem cell transplant patients 2, 4, 5
The Society for Healthcare Epidemiology of America recommends implementing standard and droplet precautions to prevent nosocomial transmission 2

The disease typically presents as upper respiratory tract infection with flu-like symptoms in patients with hMPV infection 7

Hematopoietic stem cell transplant recipients, particularly early post-transplant, are at high risk for progression to lower respiratory tract disease and severe outcomes 7
Higher corticosteroid exposure is associated with an increased risk of severe disease in patients with hMPV infection 7
Neutropenia and lymphopenia are risk factors for severe disease in patients with hMPV infection 7

Asymptomatic shedding rates may be substantial in immunocompromised populations, highlighting the need for standard and droplet precautions to prevent nosocomial transmission 7
Prolonged viral shedding has been documented in HSCT patients, emphasizing the importance of infection control measures 7
Nosocomial outbreaks can occur given the estimated incubation period of 2.6 days and high rates of asymptomatic shedding, underscoring the need for effective infection control strategies 7

The Military Medical Research recommends providing high-protein, high-vitamin, carbohydrate-containing diets for nutritional support in patients with hMPV infection 8
The Military Medical Research suggests using high-flow nasal oxygen (HFNO) or non-invasive ventilation (NIV) as initial escalation for patients developing moderate to severe ARDS from hMPV, and invasive mechanical ventilation with prone positioning for severe ARDS 8